Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this?

MeSH terms

• Antibodies, Monoclonal, Humanized* / therapeutic use
• Antineoplastic Agents, Immunological* / therapeutic use
• Carcinoma, Renal Cell* / drug therapy
• Carcinoma, Renal Cell* / mortality
• Carcinoma, Renal Cell* / surgery
• Chemotherapy, Adjuvant
• Humans
• Kidney Neoplasms* / drug therapy
• Kidney Neoplasms* / mortality
• Kidney Neoplasms* / pathology
• Kidney Neoplasms* / surgery
• Neoplasm Recurrence, Local* / prevention & control
• Nephrectomy*
• Survival Rate